Schizoaffective Disorder Clinical Trials
Effectiveness of switching from injectable conventional antipsychotic medications to injectable risperidone (PI: H. Nasrallah)
Eligibility
• Adults (at least 18 years old) with a diagnosis of schizophrenia or schizoaffective disorder who are currently receiving a first generation depot antipsychotic and have residual symptoms or side effects from this medication
• Outpatient
Patient Benefits
• Eligible participants may receive study medication and study-related procedures/visits at no cost, and compensation for participation, time, and travel
• Open-label to patient, prescribing physician, and study coordinator
Contact Information
Tracie Northern
(513) 558-0659
Tracie.Northern@uc.edu
Effectiveness of switching from polypharmacy to monotherapy (PI: H. Nasrallah)
Eligibility
• Adults (at least 18 years old) with a diagnosis of schizophrenia or schizoaffective disorder who are currently receiving two antipsychotic medications and have residual symptoms or side effects from these medications
• Outpatient
Patient Benefits
• Eligible participants may receive study medication and study-related procedures/visits at no cost, and compensation for time and travel
• Open-label to patient, prescribing physician, and study coordinator
Contact Information
Tracie Northern
(513) 558-0659
Tracie.Northern@uc.edu
Clinical management of metabolic problems in patients with schizophrenia: switching to aripiprazole versus continued treatment with olanzapine, quetiapine, or risperidone (PI: H. Nasrallah)
Eligibility
• Adults (at least 18 years old) with a diagnosis of schizophrenia or schizoaffective disorder who are currently receiving olanzapine, quetiapine, or risperidone and have residual symptoms or side effects from this medication
• Outpatient
Patient Benefits
• Eligible participants may receive study medication and study-related procedures/visits at no cost, and compensation for time and travel for outpatient visits only
• Open-label to patient, prescribing physician, and study coordinator
Contact Information
Tracie Northern
(513) 558-0659
Tracie.Northern@uc.edu
More Information
Clinical Research Management
Amelia Nasrallah, Director
University of Cincinnati Academic Health Center
Department of Psychiatry and Behavioral Neuroscience
PO Box 670559
Cincinnati, Ohio 45267-0559
Phone: (513) 558-2226
Fax: (513) 558-4616
Email: amelia.nasrallah@uc.edu